BOSTON, Aug. 9 /PRNewswire-FirstCall/ -- Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation , today announced the release of an enhanced version of its comprehensive clinical trial management system (CTMS) IMPACT(R) technology with improved site management and monitoring capabilities. With over 25,000 users in 85 countries, Perceptive Informatics’ IMPACT software is the world’s most widely used CTMS technology.
“As clients face further globalization of clinical trials and require site management and monitoring of increasingly complex studies, they need technology that keeps pace. Perceptive has enhanced its highly flexible CTMS platform to support these vital needs,” said Mark A. Goldberg, M.D., President, Clinical Research Services and Perceptive Informatics, PAREXEL International.
Dr. Goldberg added, “At PAREXEL, we have a continued commitment to using innovative technology to better serve clients. PAREXEL’s implementation of this next generation of the IMPACT technology throughout our own worldwide clinical research organization will allow us to seamlessly and securely share clinical study data with clients also using the IMPACT platform. This will promote even more efficient and effective management of their programs.”
The IMPACT software comprises several web-based modules designed to deliver practical and tangible results, decreasing the time, cost, and risk associated with the development of new products. The software provides planning and tracking support for all aspects of a clinical trial and consolidates information from various collection points into a single source. The IMPACT solution is scalable to support studies of all sizes ranging from large, multi-national studies to single center studies. The most recent version features an online and offline web-based site management and monitoring module, called MySites, which offers 24/7/365 access from anywhere in the world, enabling work on all aspects of site management including monitoring, milestone planning, issue resolution and recruitment.
“More than half of the world’s top 20 pharmaceutical companies rely on Perceptive’s IMPACT solution to manage, track, and organize the critical data involved in effectively running a clinical trial, from planning and monitoring to data collection and reporting,” said Todd A. Joron, Corporate Vice President and General Manager of Perceptive Informatics. “The enhanced IMPACT platform features a number of concrete benefits, including increased cost efficiencies, to help clients continue to improve the speed and effectiveness of their clinical development programs.”
About Perceptive Informatics, a PAREXEL Company
PAREXEL’s Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(TM) solution is Perceptive’s market-leading CTMS product with 25,000 users worldwide, and Perceptive’s INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has 6,485 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2007 as filed with the SEC on May 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL and IMPACT are registered trademarks of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Jennifer Baird, Director of Public Relations Rebecca Passo PAREXEL International SHIFT Communications Tel: +781-434-4409 Tel: +617-779-1817 Email: Jennifer.Baird@PAREXEL.com Email: rpasso@shiftcomm.com
PAREXEL
CONTACT: Jennifer Baird, Director of Public Relations of PAREXELInternational, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or RebeccaPasso of SHIFT Communications, +1-617-779-1817, rpasso@shiftcomm.com, forPAREXEL
